Category Archives: Stem Cell Treatment


Woman swears by Multiple Sclerosis remedy

IT IS expensive and controversial and the medical community is still divided about its success, but Jenni Saunders is living proof Russia's controversial stem cell treatment program can work.

The Kawana Island resident spent 30 days in Moscow in December receiving stem cell treatment she hoped would help provide some relief from the multiple sclerosis that has been slowly crippling her body for 30 years.

It has been 10 weeks since Ms Saunders' return and she is ecstatic with the results.

The 60-year-old can literally jump for joy.

It's been "years" since Ms Saunders was able to lift both feet off the ground, so the small leap in the air is a giant leap for her.

"I have seen several improvements in the last nine to 10 weeks," she said.

"The pins and needles in my hands and feet are virtually gone and I can stand up with my eyes closed.

"This might not sound like a lot to many people, but to me it is significant."

She says she is the oldest Australian to have attempted the $60,000 treatment, excluding the cost of flights.

The stem cell treatment is not approved for MS sufferers in Australia and people like Ms Saunders have to raise money to pay for the trip, even though it is available in other parts of the world.

View original post here:
Woman swears by Multiple Sclerosis remedy

Stem cellrecruiting hydrogels based on self-assembling peptides for tissue regeneration

Figure 1. Stem CellRecruiting Hydrogels Based on Self-Assembling Peptides

The Materials for Biomaterials session Best Contribution Award presented by Steve Zinkle goes to Yongmee Jung, Korea Institute of Science and Technology, for the oral presentation Self-assembling peptide nanofiber coupled with neuropeptide substance P for stem cell recruitment.

As a winner of the above Materials Today Asia Contribution Award, Yongmee Jung and Soo Hyun Kim discuss their work with us.

Stem cellbased therapy in regenerative medicine may be one of the best approaches for wound healing and tissue regeneration. Many studies have shown that the trophic effects of transplanted stem cells enhance the treatment of lung, liver, and skin injuries, as well as myocardial infarction [1]. However, although stem cell transplantationincluding cell isolation and cell culture in vitroresults in a good prognosis, there are some limitations, such as high cost, invasiveness, the shortage of cell sources, and the risk of tumorigenesis [2]. To overcome these limitations, technologies for recruiting endogenous stem cells to the site of injury may provide another promising approach, mimicking in situ tissue regeneration by the bodys own wound healing process. Unlike cell-based therapies, this strategy does not need outside cell sources or in vitro cell manipulation. Host stem cells can be mobilized using granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stromal cellderived factor-1 alpha (SDF-1), each of which upregulates adhesion molecules and activates chemokine signaling [3]. It has been reported that substance P (SP), another candidate for recruitment of host stem cells, is an injury-inducible factor that acts early in the wound healing process to mobilize CD29+ stromal-like cells, and thus could be used for tissue regeneration [1].

To achieve effective delivery of SP for an extended period and improve the engraftment of recruited cells at the injured site, scaffolds can be constructed from hydrogels with microenvironments similar to the native tissue. Of particular interest are self-assembling peptide (SAP)based hydrogels, which are typically composed of alternating hydrophilic and hydrophobic amino acids organized into 510 nm fibers and assembled into three-dimensional nanofibrous structures under in vivo conditions [4]. The resulting structure resembles nanostructured environments such as collagen hierarchical structures that promote adhesion, proliferation, and differentiation of cells. Furthermore, SAP is versatile enough to incorporate specific motifs based on the desired function with chemical coupling by peptide bond [5].

Recently, we designed bioactive peptide hydrogels that are able to recruit mesenchymal stem cells by coupling SAP to SP. The mixture of SAP and SP-coupled SAP can successfully maintain its nanofibrous structure and be assembled into a 3D scaffold at physiological conditions.

We confirmed the ability of this SP-coupled SAP to attract stem cells both by in vitro cell migration assay and by in vivo real-time cell tracking assay. In vitro, many cells migrated through the 8-m membrane pores and settled onto the lower surfaces of Transwell plates under the influence of SP-coupled SAP. In vivo, we injected the hydrogels into the subcutaneous tissue in nude mice and injected labeled human mesenchymal stem cells (hMSCs) into the tail vein. The migration of the injected cells was tracked in real time using a multispectral imaging system, which demonstrated that the labeled hMSCs supplied via intravenous injection were recruited to the hydrogel-injected site (Figure) [6]. We then applied our bioactive peptide hydrogels, SAP coupled with SP, to several disease models to evaluate their stem cell recruitment abilities and treatment effects on injured tissues. We have studied the effects of these hydrogels on animal models of ischemic hind limb, calvarial defect, myocardial infarction, osteoarthritis, and skin wounds. We observed in each case that in the group treated with SP-coupled peptide hydrogels, many MSCs were recruited to the injured sites, and cell apoptosis and fibrosis of injured tissues were both conspicuously decreased. Moreover, the regeneration of site-specific tissues was enhanced with the injection of stem cellrecruiting peptide hydrogels in various defect models, and tissue functions were accordingly improved without cell transplantation [2, 5, 6]. In conclusion, we have developed injectable bioactive peptides that can recruit MSCs and have evaluated their therapeutic potential on animal defect models. By applying these peptide hydrogels, we were able to deliver SP over an extended period and provide 3D microenvironments to injured regions, allowing bioactive peptides to recruit MSCs successfully, prevent cell apoptosis, and promote tissue regeneration leading to a full recovery of defects. We expect that stem cellrecruiting hydrogels based on SAP could be one of the most powerful tools for tissue regeneration without cell transplantation through the recruitment of endogenous stem cells.

This work was supported by the KIST Institutional Program

1. H. S. Hong, et al., Nat. Med., 15 (2009), pp. 425435 2. J. H. Kim, et al., Biomaterials, 34 (2013), pp. 16571668 3. T. Lapidot, I. Petit, Exp. Hematol., 30 (2002), pp. 973981 4. S. Zhang, et al., Semin. Cancer Biol., 15 (5) (2005), pp. 413420 5. J. E. Kim, et al., Int. J. Nanomedicine, 9 (Suppl 1) (2014), pp. 141157 6. S. H. Kim, et al., Tissue Eng. Part A, E-Pub (2014)

More here:
Stem cellrecruiting hydrogels based on self-assembling peptides for tissue regeneration

Brave gran set to take on 10,000ft skydive to help pay for life-saving medical treatment for daughter

A GRAN who is afraid of heights is set to skydive from 10,000ft to help pay for life-saving medical treatment for her daughter.

Margaret Clarke, 70, aims to overcome her lifelong fear so Lucy, 38, can travel to Moscow for a pioneering stem cell transplant to stop the progression of Multiple Sclerosis.

The skydive over St Andrews, Fife is one of several fundraising initiatives Lucy's family are undertaking to raise the 40,000 needed for the treatment.

If the mum-of-one can secure funding she will be the first Scot to fly to Russia for the cutting edge procedure.

Margaret, of Rosehall, Sutherland, said: Which mother wouldnt jump out of a plane at 10,000 feet if they thought it would save their daughter?

I dont think Im any different from any other caring mother.

Lucy has suffered terribly with her illness.

Multiple Sclerosis is a disease that gets progressively worse over time.

If we dont act now, I dont want to think about where we will be in a few years time.

The jump on March 29 is one of a number of charity events planned to raise money for mum-of-one Lucy's treatment.

Originally posted here:
Brave gran set to take on 10,000ft skydive to help pay for life-saving medical treatment for daughter

Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage – 6 Months After Stemcell Transplant – Video


Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant
Bruce from Perth Australia give us an update 6 Months After his cord Mesenchymal stem cell treatment for Iiver cirrhosis, kidney complications in Thailand: More here: http://stemcellthailand.org/th...

By: Regeneration Center of Thailand

See original here:
Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant - Video

Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris – Analyst Blog

Seattle Genetics, Inc. ( SGEN ) announced the submission of a supplemental biologics license application (BLA) to the FDA for Adcetris as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in patients suffering from Hodgkin lymphoma, who are at a high risk of relapse.

The company submitted the BLA on the basis of positive data from the phase III AETHERA study.

We note that Adcetris is already approved for intravenous injection in the U.S. (accelerated approval) and the EU (conditional marketing authorization) for the treatment of patients with Hodgkin lymphoma after the failure of ASCT or at least two previous multi-agent chemotherapy regimens in patients who have not undergone ASCT.

The drug also received accelerated approval for systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen in the U.S. and conditional marketing authorization for relapsed or refractory sALCL in the EU.

Adcetris is being developed by Seattle Genetics in partnership with Takeda Pharmaceutical ( TKPYY ). According to the agreement, Seattle Genetics holds the commercialization rights to Adcetris in the U.S. and Canada, while Takeda has the rights in the rest of the world. Both companies share development costs for Adcetris equally, except in Japan where Takeda bears the entire costs of development.

Apart from the AETHERA study, both companies are evaluating Adcetris in three phase III studies - ALCANZA (relapsed cutaneous T-cell lymphoma), ECHELON-1 (front-line advanced classical Hodgkin lymphoma) and ECHELON-2 (front-line mature T-cell lymphoma including sALCL). Data from the ALCANZA study should be out in 2016.

Meanwhile, Seattle Genetics is also working on developing its pipeline beyond Adcetris. The company has several early-stage candidates in its pipeline including six antibody drug conjugates - SGN-CD19A, SGN-CD33A, SGN-LIV1A, SGN-CD70A, ASG-22ME and ASG-15ME. Earlier this week, Seattle Genetics initiated a phase I study on its investigational immuno-oncology agent, SEA-CD40, for multiple types of advanced solid tumors.

Seattle Genetics carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are BioMarin Pharmaceutical Inc. ( BMRN ) and Cytokinetics, Inc ( CYTK ). While Cytokinetics carries a Zacks Rank #1 (Strong Buy), BioMarin holds a Zacks Rank #2 (Buy).

SEATTLE GENETIC (SGEN): Free Stock Analysis Report

BIOMARIN PHARMA (BMRN): Free Stock Analysis Report

Continue reading here:
Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog

Stem Cell Treatment for Mr. Hockey Stirs Controversy

Any hockey fan would recognize Mr. Hockey Gordie Howe and remember the former Red Wing star as one of the toughest players in the history of the game. His name is famously, if somewhat incorrectly, connected to the unofficial Gordie Howe Hat Trick, in which a player records a goal, an assist, and a fight in the same game. His remarkable career spanned six decades, including a record-setting five in the NHL, and his contributions to the game have lasted long after his retirement.

Struck By Illness

Sadly, Howe suffered a severe stroke in October of 2014. Friends, family, and fans expected the worst. The 86-year-old legends condition seemed to deteriorate rapidly. When he was released to his daughters home in Texas, many people thought Mr. Hockey would not survive long. Then surprising news of significant recovery began to surface. On February 6, Howe made an almost unbelievable public appearance and looked quite well considering what hed been through.

Controversial Treatment

It is now being widely reported that, in December, Howe underwent a stem cell treatment in Mexico. The treatment was developed by San Diego-based Stemedica. Since then, Mr. Hockey has been on the mend. But many experts are questioning whether it was the stem cell treatment, and whether such treatments are safe and reliable. Stem cell treatments are brand new, and many medical professionals believe the results are unproven.

As the debate rages on, the Howe family and many other people in dire medical straits now believe that stem cell treatment can give them hope for meaningful treatment and recovery.

Read the rest here:
Stem Cell Treatment for Mr. Hockey Stirs Controversy

Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities

ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX) and its subsidiary Cell Cure Neurosciences Ltd. (Cell Cure) today provided an update on Cell Cures product development and partnering activities.

On February 16, 2015, Cell Cure opened the clinical trial of OpRegen titled Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial (RPE) cells with high purity and potency.

On October 31, 2014, the United States Food and Drug Administration (FDA) cleared Cell Cure's Investigational New Drug (IND) application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration (AMD) with geographic atrophy (GA). While treatment options exist for the treatment of the wet form of AMD, it amounts to only about 10% of the disease prevalence. There is currently no FDA-approved therapy for the dry form occurring in approximately 90% of those afflicted with AMD. Cell Cure intends to transplant OpRegen as a single dose into the subretinal space of patients eyes in order to test the safety and efficacy of the product in this leading cause of blindness.

The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion.

Cell Cure also announced today that the option granted to Teva Pharmaceutical Industries Ltd. (Teva) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product.

Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells (the active ingredient of OpRegen) is expected to issue on February 17, 2015. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.

The large markets currently associated with therapies for the wet form of AMD combined with the elegance of RPE replacement therapy for the larger unmet needs associated with the dry form, highlights why Cell Cure has prioritized the development of this product, said Dr. Charles Irving, CEO of Cell Cure. We look forward to initiation of the trials and providing updates in the coming months.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly but may progress to geographic atrophy (GA) in which RPE cells and photoreceptors degenerate and are lost. Once the atrophy involves the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There are about 1.6 million new cases of dry-AMD in the US annually, and as yet there is no effective treatment for this condition. About 10% of patients with dry-AMD develop wet (or neovascular) AMD, the second main form of this disease, which usually manifests acutely and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently-marketed VEGF inhibitors. However, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from continued progression of the underlying dry-AMD disease process. Current estimated annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be in excess of $5 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to support and replace the patients old degenerating RPE cells, which may prevent progression of the atrophy as well as the development of wet-AMD. Pluripotent stem cells, such as hESCs, can provide an unlimited source for the derivation of such healthy RPE cells for transplantation.

About OpRegen

Go here to read the rest:
Cell Cure Neurosciences Ltd. Provides Update on its Product Development and Partnering Activities

Dr. Raj at Beverly Hills Orthopedic Institute Achieving 80% Success with Stem Cell Therapy

Beverly Hills, CA (PRWEB) February 17, 2015

The top stem cell clinic in Los Angeles and Beverly Hills is now achieving 80% success with stem cell therapy for all types of arthritis and soft tissue indications. This includes hip, knee, shoulder, elbow and ankle injections for helping patients achieve pain relief and avoid surgery. Call (310) 438-5343 for more information on the treatment options available and scheduling.

Dr. Raj, who was recently named a Super Doc Southern California for the 4th year in a row, has been performing stem cell therapy on patients for years. This includes athletes, weekend warriors, celebrities, executives, senior citizens and students as well.

There are two methods offered for the treatment, one of which is Bone Marrow derived. This includes harvesting bone marrow from the patient's hip area, and then the material is immediately processed to concentrate the stem cells and growth factors. the fluid is then injected into the problem area. An internal review at Beverly Hills Orthopedic Institute has shown that 80% of patients achieve excellent pain relief and increased functional abilities. This includes getting back to athletics, recreational activities and walking more.

The second method of treatment involves amniotic derived stem cell rich injections. The amniotic fluid is processed at an FDA regulated lab, with no fetal tissue being involved and no embryonic stem cells at all. Amniotic fluid has been used tens of thousands of times worldwide for many indications, and contains growth factors, hyaluronic acid and stem cells.

Indications for the treatment include tennis and golfer's elbow, plantar fasciitis, degenerative arthritis of the hip, knee, shoulder, elbow, ankle, ligament injuries, and tendonitis of the shoulder, knee, achilles and more.

Dr. Raj is a Double Board Certified orthopedic doctor in Los Angeles and serves as an ABC News Medical Correspondent and a WebMD expert. He is called frequently by networks for his opinion on orthopedic matters, and is on the Medical Advisory Board for R3 Stem Cell.

For more information and scheduling with the top stem cell clinic in Los Angeles and Beverly Hills, call (310) 438-5343.

Go here to see the original:
Dr. Raj at Beverly Hills Orthopedic Institute Achieving 80% Success with Stem Cell Therapy

Changing stem cell structure can tackle obesity

Slight regulation in the length of primary cilia -- small hair-like projections found on most cells -- can prevent the production of fat cells from human stem cells taken from an adult bone marrow, reveals new research.

"This is the first time that it has been shown that subtle changes in primary cilia structure can influence the differentiation of stem cell into fat.

"Since primary cilia length can be influenced by various factors including pharmaceuticals, inflammation and even mechanical forces, this study provides new insight into the regulation of fat cell formation and obesity," said co-author Melis Dalbay of Queen Mary University of London (QMUL).

Part of the process by which calories are turned into fat involves Adipogenesis, the differentiation of stem cells into fat cells.

The researchers showed that during this process of Adipogenesis, the length of primary cilia increases associated with movement of specific proteins onto the cilia.

Furthermore, by genetically restricting this cilia elongation in stem cells the researchers were able to stop the formation of new fat cells.

Recent research has found that many conditions including kidney disease, blindness, problems with bones and obesity can be caused by defects in primary cilia.

"This research points towards a new type of treatment known as 'cilia-therapy' where manipulation of primary cilia may be used in future to treat a growing range of conditions including obesity, cancer, inflammation and arthritis," said lead author prof Martin Knight.

See the rest here:
Changing stem cell structure can tackle obesity